The oestrogen receptor and its selective modulators in gynaecological oncology.
Seifert
M
M
University of Vienna Department for Special Gynecology, Vienna, Austria.
Galid
A
A
Kubista
E
E
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D002934:Cinnamates / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D009652:Norpregnenes / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013267:Stilbenes / Q000627:therapeutic use; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D017312:Toremifene / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D002934:Cinnamates; D004965:Estrogen Antagonists; D009652:Norpregnenes; D010880:Piperidines; D020845:Selective Estrogen Receptor Modulators; D013267:Stilbenes; D013876:Thiophenes; D013629:Tamoxifen; C064635:TAT 59; C087550:3-(4-(1,2-diphenylbut-1-enyl)phenyl)acrylic acid; C071362:idoxifene; D020849:Raloxifene Hydrochloride; D017312:Toremifene; C115121:LY 353381; C027385:tibolone